spartex, I appreciate your reply to my post. But, I stand by my post. Here is the exact quote from Merck’s CEO, Ken Frazier:
Of course, “bigger and later-stage” comes with a heftier price tag—and Frazier is well aware. In a not-so-subtle reference to Gilead’s $21 billion Immunomedics buy, he mentioned the “very large prices” that have been attached to biopharma deals made in the last year or so.
"Right now, biotech’s at an all-time high," Frazier said.
"If you're going to try to acquire those assets right now," he added, "you’re going to pay a very steep price, and then a premium on top of it. And on top of that, anytime somebody’s going after something, it turns into a bidding war."
The kind of assets Ken Frazier is talking about, that could cause a “bidding war”, are “bigger”, “later-stage” (Phase IIII) “biotech” assets. Those asset descriptions fit DCVax-L perfectly, IMO.
PS: I do not expect Merck to acquire NWBio before NWBio releases the DCVax-L Phase III data, and the subsequent significant increase in the NWBO share price & market cap.
Market Data 
Markets 
AI
